Drug Profile
Research programme: phosphodiesterase IV inhibitors - Dart NeuroScience
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Helicon Therapeutics
- Developer Dart NeuroScience
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cognition-disorders in USA
- 01 Jan 2012 Helicon Therapeutics has been acquired and merged into Dart NeuroScience
- 11 Apr 2011 Early research in Cognition disorders in USA (unspecified route)